Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma indications, there is ...

Q4 2024 Management View CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to ...

“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma ...